Last Updated on October 12, 2025 by The Health Master
USFDA approval
Alembic Pharmaceuticals revealed that the United States Food and Drug Administration final approval (USFDA approval) to sell Phytonadione Injectable Emulsion in the American market.
This is a big step forward for the drug to become available to needy patients.
What Does the Drug Do?
You can consider this as an essential reliever for the human body.
Phytonadione the injectable emulsion form of this vitamin K acts as a lifesaver for those who bleed more than expected.
It’s indicated in treating and preventing vitamin K-deficiency bleeding, notably in infants something that could be known as hemorrhagic disease of the newborn.
In addition, it assists patients with hypoprothrombinemia a condition when the human body fails to synthesize all proteins necessary for blood clotting.
Therefore, its easy accessibility in the injectable format is crucial for all hospitals and outpatient departments.
Which Drug is It Equivalent To?
The fascinating aspect of this USFDA approval is that Alembic’s version is considered therapeutically equivalent to the one already marketed by International Medication Systems Limited.
Thus, it would be just as safe and effective as the original medication.
Alembic’s version will also be available in prefilled syringes for easy access.
How Important Is It for Alembic?
It’s essential not only for patients but also for Alembic as a developing company because the market size of this drug stands at $44 million annually for this particular formulation in the United States.
Therefore, if Alembic captures even a small portion, it would mean much new business.
For the Gujarat-based drugmaker, this USFDA approval marks 225 total approvals for drugs with generic applications.
This also includes 204 final approvals and 21 tentative approvals, demonstrating stability and consistent progress in establishing itself in the US drug market.
Q: What is an ANDA application?
ANDA stands for Abbreviated New Drug Application. This is how a company files a request to the USFDA to sell a generic version of an already-approved branded product on the market. The “abbreviated” means that they do not have to go through the extensive and expensive clinical trial process to prove safety and efficacy; instead, they must show that their generic does what the branded version does.
Q: What’s the difference between a “final” and “tentative” USFDA approval?
A final USFDA approval is given when a drug can be marketed in the US immediately, while a tentative USFDA approval is granted when a drug is ready to go but there is a hurdle, which often means the branded product has an active patent or exclusivity period that has not yet lapsed. Once it does lapse, the tentative USFDA approval can be turned into a final USFDA approval.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Disclaimer: The information we have provided is for general knowledge and for informational purpose only and it cannot be treated as medical advice. Always consult your doctor for any health issues and / or for the treatment of the same. The Health Master does not claim responsibility for this information.
USFDA puts import Alert on Sun Pharma: Halol
USFDA issued Form 483 to Biocon with 5 observations
USFDA issued Form 483 to Aurobindo with 8 observations
USFDA issued Form 483 to Alembic Pharma with 1 observation
USFDA issued Form 483 with two observations to Aurobindo for API plant
USFDA puts import Alert on Sun Pharma: Halol
Indian Drug Regulation Goes 97% Digital: CDSCO
5 Northern State SDCs Unite Against Counterfeit Drugs
USFDA issued Form 483 to Biocon with 5 observations
USFDA issued Form 483 to Aurobindo with 8 observations
Drug recall: Unichem recalls Cyclobenzaprine HCL Tablets
Govt. amends Uniform Code for Marketing Medical Devices
Govt to amend Clinical Trials Rules to speed up approvals
